SCH772984

For research use only.

Catalog No.S7101

372 publications

SCH772984 Chemical Structure

CAS No. 942183-80-4

SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells.

Size Price Stock Quantity  
USD 270 In stock
USD 1349 In stock
USD 5390 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's SCH772984 has been cited by 372 publications

Purity & Quality Control

Choose Selective ERK Inhibitors

Biological Activity

Description SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells.
Features Does not directly inhibit MEK1, MEK2, BRAF, or CRAF enzyme activity.
Targets
ERK2 [1]
(Cell-free assay)
ERK1 [1]
(Cell-free assay)
1 nM 4 nM
In vitro

SCH772984 is a novel, selective and ATP competitive inhibitor of ERK1/2. SCH772984 inhibits phosphorylation of the ERK substrate p90 ribosomal S6 kinase (T359/S363 phospho-RSK) in a dose-dependent manner. SCH772984 also inhibits phosphorylation of residues in the activation loop of ERK itself. SCH772984 demonstrates EC50 values <500 nM in approximately 88% and 49% of BRAF-mutant or RAS-mutant tumor lines, respectively. Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
2P-ERK2 NHXYc|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIOyXXFKSzVyPUCuNlQhdk1? NGnW[mM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO1NFk{OSd-MkWzOVA6OzF:L3G+
WM-266-4 M4Sy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjEVGJKSzVyPUKwJI5O MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
UACC-62 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESzN2pKSzVyPUOwJI5O NHTpPYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
Colo-205 M{\sb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\BTWM2OD1|NjDuUS=> M3;YbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SK-Mel-1 MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrITWM2OD1|NzDuUS=> NXfZWo1[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
WiDr NVfGfoM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfNUnhKSzVyPUO5JI5O M1z2dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
M14 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjrTWM2OD12NzDuUS=> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
HT-29 MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHQOlhKSzVyPUWwJI5O MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
8505C NF63Vm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHCc5BLUUN3ME21NEBvVQ>? M2PYflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HT-144 NVmzRmxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnuSYdKSzVyPU[wJI5O MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SK-Mel-5 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojETWM2OD14NjDuUS=> NUHROGdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
A375-SM M2\QXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T6fGlEPTB;N{Wgcm0> NGLJTWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
SK-Mel-28 M{XweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;tNVJKSzVyPUi1JI5O MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
LOX NEXJXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFyMDDuUS=> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SK-Mel-3 NFXX[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPFSpZFUUN3ME2xNVghdk1? MnvTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
K1 M3qyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF|MDDuUS=> M1;mUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
Hs-695T MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zwdWlEPTB;MU[1JI5O NFnVVWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
BHT-101 NIG1Z5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrkdY5DUUN3ME2zNFAhdk1? MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
RPMI-7951 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;w[WlEPTB;M{S0JI5O MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
A2058 NGTwbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXZWVNQUUN3ME2zOlAhdk1? NYHhSZRvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SK-Hep-1 MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF2MkKgcm0> NH\ER2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
A673 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzuTWM2OD1|MECxJI5O MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
DBTRG-05MG NVfrb4Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K4OmlEPTB;M{CwNUBvVQ>? M2PCR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SW-626 MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn6dZdKSzVyPUOzJI5O M3\SRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
LoVo NX[5enc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjidHRiUUN3ME20O{BvVQ>? MmfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
MiaPaCa M4ftNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDLTWM2OD13MzDuUS=> NXXFeGVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SW-620 NX;ETlJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;kPGlEPTB;MUC0JI5O Mlr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
CAPAN-1 NXr3[Ys3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3GTWM2OD1zMESgcm0> MmrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
SW-527 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF{MTDuUS=> MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
HCT-116 NW\IRlNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TPeGlEPTB;MUK4JI5O MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SW-480 M4HrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojXTWM2OD1zNkWgcm0> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
HPAC NUjWeW5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLuTWM2OD1zN{Cgcm0> NF3ubpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
OVCAR-5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq2WnF[UUN3ME2yNFghdk1? M3nNW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
AsPc-1 NXLScIhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Gz[2lEPTB;MkewJI5O NX:zXI13RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
A549 NGjmWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HHT2lEPTB;M{K2JI5O NX;m[3JORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SNU-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn1emVCUUN3ME2zOVQhdk1? M4nuV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HOP62 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljUTWM2OD14N{[gcm0> NWXIV5UyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
H23 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LFWWlEPTB;MUCwNEBvVQ>? MmfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
MB-231 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCxNYdMUUN3ME2xNFAxKG6P MnnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
SU.86.86 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLKTWM2OD1zMECxJI5O M2LLO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
CFPAC-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfITWM2OD1zMECxJI5O MmO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
A427 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLITWM2OD1zNEOzJI5O M132V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
MDAH-2774 NYm0[I9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PX[mlEPTB;Mk[1O{BvVQ>? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
NCI-H157 M4G2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzWTWM2OD1|MECwJI5O Mn2yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
HTB-177 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInSdZlKSzVyPUOwNFAhdk1? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
UM-UC-3 NFm2XXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn1UWlKSzVyPUOwNFEhdk1? NXPoT2RXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
HCT-8 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXGWnlKSzVyPUOwNFEhdk1? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
Panc-1 MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvLTWM2OD1|MECxJI5O M1r2N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
DLD-1 NUewRYZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\2Wo9KSzVyPUOwNFEhdk1? NIjvcZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
HCT-15 NXfCTZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTNyMEGgcm0> M1\kflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HL-60 NGT2OVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;o[GlEPTB;M{Cgcm0> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SK-Mel-2 MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTN2IH7N MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
RD NGD0VZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF{MzDuUS=> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
HT-1197 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17FeGlEPTB;M{G2JI5O NIPzeHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
Molt-3 NHfRV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPFdVBKSzVyPU[wNEBvVQ>? NGfuWJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
PA-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\se3I{UUN3ME2xNFAyKG6P NYfPOWF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
Molt-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX4[o91UUN3ME2zNFAyKG6P NVfMW|h7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
NCI-H292 NGLac29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX0TW9KSzVyPUmwJI5O M4rLUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
A2780 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF2MzDuUS=> NITWR2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
IGROV-1 NGPUdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H3cWlEPTB;MUS2JI5O NYXNNoY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SK-N-SH M1fiSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDvPVdtUUN3ME2xOVAhdk1? NXuwNFdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
N-87 NV7COGJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml32TWM2OD1|MEegcm0> M{nK[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
H322 NUj2UllPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7nPJQ1UUN3ME2zNlUhdk1? MnzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
H716 NIez[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH5bVNKSzVyPUOzOEBvVQ>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
TT NGXtblVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nYeGlEPTB;NEC2JI5O MnL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
Caki-1 NFK1blBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y2SmlEPTB;NEWwJI5O MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
5637 M2PINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn6[nZuUUN3ME22NVAhdk1? NUXvWWhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
MB-453 NYLsN2l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TOUGlEPTB;NkeyJI5O M2LxSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
RT-4 NGDmZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfzTo1KSzVyPUixNEBvVQ>? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
HOP92 NVvubWxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTtdY5KSzVyPUiyNEBvVQ>? NYjDNY43RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
KG-1 NFzQb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTlyMDDuUS=> M{XsXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
Hs-294T NX\jendtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTl2NTDuUS=> M2DKW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SF-539 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P2VGlEPTB;MUCwNEBvVQ>? NUfpSmxtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
U-251 NFXIcG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV74PFU{UUN3ME2xNFAxKG6P NU\zcWlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
MB-468 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFyMECgcm0> NHTwOpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
HS746T NEOyPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofzTWM2OD1zMECwJI5O NFW5PGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
SCABER M4DKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPwRYRPUUN3ME2xNFAxKG6P NYntfpVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
MCF-7 NFnh[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7OcWFKSzVyPUGwNFEhdk1? M2PaWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
CHL-1 NVTRWGwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF2NkCgcm0> NU\qVoJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
U87MG NVPyOmJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnZZlBKSzVyPUKwNFAhdk1? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SJCRH30 NVOzSnRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu0Xo5KSzVyPUKwNFIhdk1? M3O5U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
ES-2 NUDFNoh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm0ZXdKSzVyPUK2OVkhdk1? NH73dI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
HT-1376 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPyT5NKSzVyPUK4NFAhdk1? NInjZlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
A172 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITOSW9KSzVyPUOwNFAhdk1? M3XxZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
769P MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDKfWZKSzVyPUOwNFAhdk1? NF7BU5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
NCI-H520 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n2bGlEPTB;M{CwNEBvVQ>? NHfkd409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
DU145 Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTNyMECgcm0> NGfxbXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
K562 MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTNyMECgcm0> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
U-937 NHixUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n0PGlEPTB;M{CwNEBvVQ>? NET6UWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
A204 NV7rdnhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi2OmlKSzVyPUOwNFEhdk1? MnH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
DAOY M3\q[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNyMEGgcm0> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SF-268 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTNyMEGgcm0> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SF-295 NF\QT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe1bJhqUUN3ME2zNFAyKG6P MnuxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
SNB-19 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFK5NHlKSzVyPUOwNFEhdk1? NXTOSoxkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SNB-75 NF;CW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHERVBKSzVyPUOwNFEhdk1? MoLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
U373-MG NXXYc3J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i1SWlEPTB;M{CwNUBvVQ>? Mm\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
786-O Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;uT3cxUUN3ME2zNFAyKG6P NFLGTXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
A498 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nLTGlEPTB;M{CwNUBvVQ>? M4m5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
ACHN NYPYT29zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq0[HFKSzVyPUOwNFEhdk1? MkXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
EKVX NF73VJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInDTVlKSzVyPUOwNFEhdk1? M3m2fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
H226 NUjnZXNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\ySmVyUUN3ME2zNFAyKG6P NVHrWFFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
H522 Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDiTWM2OD1|MECxJI5O Mn\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
HeLa NWTIeGFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTNyMEGgcm0> NHXjbYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
SK-OV-3 M4PC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFK3VWtKSzVyPUOwNFEhdk1? NIniT5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
Ln Cap M3fWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrsXVFKSzVyPUOwNFEhdk1? Mn7MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
PC3 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTxTWM2OD1|MECxJI5O M170N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SNU-16 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL2dlNKSzVyPUOwNFEhdk1? MmnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
FTC-133 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLpN3ZKSzVyPUOwNFEhdk1? M3PqdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
Ro82-W-1 NED1TWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTNyMEGgcm0> Mk\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
Daudi NGT4OWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe5SXdMUUN3ME2zNFAyKG6P MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
Jijoye NYroXoFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f2[2lEPTB;M{CwNUBvVQ>? NEnKTno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
Jurkat MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXnbHBYUUN3ME2zNFAyKG6P M3vpbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
J-82 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK0TWM2OD1|MECxJI5O M376PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
TCC-SUP MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlK1TWM2OD1|MECxJI5O NV;RU4FbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
BT-474 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:yVpRWUUN3ME2zNFAyKG6P M4faSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
ZR-75-1 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnftTWM2OD1|MECxJI5O MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
A375 MmTkSpVv[3Srb36gZZN{[Xl? Mn[0NkBpenN? NEXEWIpKdmirYnn0bY9vKG:oIFXST|IhcW5iaIXtZY4hSTN5NTDj[YxteyCqYYLic5JqdmdiQj3SRWYhXjZyMFWgcZV1[W62IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHCqb4PwbI8uTVKNMjDs[ZZmdCCjZoTldkAzKGi{czDifUBE\Wyub33pZ5MhSXK{YYnTZ4FvXE1iVmTJJIlu[WerbnegZY5idHm|aYOsJGlEPTBiPTCwMlAxPCEQvF2u NEHXSG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm3O|k5OSd-MkW5O|c6QDF:L3G+
A375 MlfvSpVv[3Srb36gZZN{[Xl? NYLkUGFPUW6qaXLpeIlwdiCxZjDFVmszKGmwIHj1cYFvKEF|N{WgZ4VtdHNiaHHyZo9zcW6pIFLSRWYhXjZyMFWgcZV1[W62IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGVTUzJibHX2[Yx{NCCLQ{WwJF0hOC5yMESg{txONg>? NUfQSJBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizO|Y{ODZpPkK4N|c3OzB4PD;hQi=>
COLO205 MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NF\PUXI1KGSjeYO= M2LJcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1;MU|IxPSClZXzsd{Bp[XKkb4LpcochSlKDRjDWOlAxTS:GIH31eIFvfCCvZXHzeZJm\CCjZoTldkA1KGSjeYOsJGlEPTBiPTCwMlAyPiEQvF2u MkPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NVUoRjNyMEO0OlE2RC:jPh?=
A375 NYrJUVZwTnWwY4Tpc44h[XO|YYm= MonYNkBpenN? NILiOFBKdmirYnn0bY9vKG:oIFXST|EwOiCrbjDoeY1idiCDM{e1JINmdGy|IHjhdoJwemmwZzDCMXJCTiCYNkCwSUBufXSjboSgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpdy2UU1ugcIV3\WxiYX\0[ZIhOiCqcoOgZpkhS2WubH;tbYN{KEG{cnH5V4NidlSPIG\UTUBqdWGpaX7nJIFv[Wy7c3nzMEBKSzVyIE2gNE4xOiEQvF2u M2HnNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUe3PVgyLz5{NUm3O|k5OTxxYU6=
A375 NFzWcFhHfW6ldHnvckBie3OjeR?= M{TTWFIhcHK| MVrJcohq[mm2aX;uJI9nKEWUS{GvNkBqdiCqdX3hckBCOzd3IHPlcIx{KGijcnLvdolv\yCELWLBSkBXPjByRTDteZRidnRiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4heGixc4Doc{1TW0tibHX2[Ywh[W[2ZYKgNkBpenNiYomgR4VtdG:vaXPzJGFzemG7U3PhcnROKF[WSTDpcYFocW6pIHHuZYx6e2m|LDDJR|UxKD1iMD6wNkDPxE1w NInTbXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm3O|k5OSd-MkW5O|c6QDF:L3G+
A375 NXXZbph2TnWwY4Tpc44h[XO|YYm= NFO2R4VKdmirYnn0bY9vKG:oIFXST|IhcW5iaIXtZY4hSTN5NTDj[YxteyCqYYLic5JqdmdiQmLBSkBXPjByRTDteZRidnRiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4heGixc4Doc5J6dGG2ZXSgVnNMKGyndnXsd{whUUN3MDC9JFAvODJizszNMi=> NHu1Upg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO3OlMxPid-MkizO|Y{ODZ:L3G+
HT-29 NWLzcJRqSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M3eyNlQh\GG7cx?= NXfaZnZTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bp[XKkb4LpcochSlKDRjDWOlAxTS:GIH31eIFvfCCvZXHzeZJm\CCjZoTldkA1KGSjeYOsJGlEPTBiPTCwMlA2QSEQvF2u NXvNNG5WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN|Q3OTVpPkOwNFM1PjF3PD;hQi=>
HT-29 M1\kTWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MnjWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDoZZJjd3KrbnegRnJCTi:NUlHTJI12fGGwdDygTWM2OCB;IECuNFU6KM7:TT6= MnnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NEiwOVEoRjJ7N{S4NFUyRC:jPh?=
A375 NV\RUmk3SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MUe3NkBpenN? MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF|N{WgZ4VtdHNiaHHyZo9zcW6pIFKtVmFHKFZ4MEDFJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscI9ucWO|IFHydoF6W2OjbmTNJHZVUSCrbXHnbY5oKGGwYXz5d4l{NCCLQ{WwJF0hOC5yNzFOwG0v NGLvR3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm3O|k5OSd-MkW5O|c6QDF:L3G+
HT-29 NG\OU|hCeG:ydH;zbZMh[XO|YYm= MVfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiWLUK5JINmdGy|IHjhdoJwemmwZzDCVmFHN0uUQWOgcZV1[W62IHL5JINie3Cjc3WgZYN1cX[jdHnvckBie3OjeTygTWM2OCB;IECuNFk3KM7:TT6= MmXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NEiwOVEoRjJ7N{S4NFUyRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cyclin B1 / cyclin D1 / p21; 

PubMed: 26725216     


Cells treated as above were collected for western blot for total cyclin B1, cyclin D1 and p21, and of phosphorylated, inactivated RB (S807/811; pRB). Western blot for pERK was done to verify SCH772984 inhibition; β-actin was the loading control.

pRSK / pERK / pAKT / pMEK; 

PubMed: 26725216     


Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984, then evaluated by western blot with phospho-specific antibodies for RSK (T395/S363; pRSK), MEK1/2 (S217/221; pMEK), AKT (S473; pAKT), and ERK (T202/Y204; pERK). Total RSK, ERK, AKT, MEK and β-actin were also analyzed. Data are representative of three independent experiments.

DUSP1 / DUSP4 / DUSP6; 

PubMed: 26725216     


Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984 for 72 hr and evaluated by western blot for DUSP1, DUSP4, DUSP6 and β-actin.

pCRAF(S338, S289, S296, S301); 

PubMed: 26725216     


Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984 for 72 hr and evaluated by western blot for pCRAF (S338), pCRAF (S289/296/301), total CRAF and β-actin.

Aurora B / ETS1 / ETS2; 

PubMed: 26725216     


Cells were treated with vehicle or SCH772984 for 7 days, then immunoblotted for Aurora B, MYC, ETS1 or ETS2, and β-actin. Data are representative of three independent experiments.

26725216
Growth inhibition assay
Cell viability; 

PubMed: 30118499     


NCI-H747, SW837, SW480, and SW620 cells were treated with the ERK inhibitor SCH772984 at indicated concentrations for 72 hours. Dimethyl sulfoxide (DMSO) (0.01%) was used as the control treatment. Each data point represents the mean of five replicates; error bars indicate one SD.

30118499
Immunofluorescence
TOMM20; 

PubMed: 30833752     


Mitochondrial morphologies of PDAC cells treated with SCH772984 (ERKi, 1 µM) for 24 h. Green, Anti-TOMM20; blue, DAPI; scale bar, 20 μm.

pERK1/2; 

PubMed: 30213106     


After treatment with 10 µM of the ERIK1/2 inhibitors, the expression of p-ERK1/2 protein in HeLa cells was detected using immunofluorescence (400×), bar = 50 μm.

30833752 30213106
In vivo SCH772984 induces tumor regressions in xenograft models at tolerated doses. SCH772984 effectively inhibites MAPK signaling and cell proliferation in BRAF or MEK inhibitor resistant models. [1]

Protocol

Kinase Assay:

[1]

- Collapse

ERK2 IMAP enzymatic assay:

SCH772984 is tested in 8 point dilution curves in duplicate against purified ERK2 or ERK1. The enzyme is added to the reaction plate. and incubated with the compound before adding a solution of substrate peptide and ATP. 14μl of diluted enzyme (0.3ng active ERK2 per reaction) is added to each well of a 384-well plate. The plates are gently shaken to mix the reagents and incubated for 45 minutes at room temperature. The reaction is stopped with 60μl of IMAP Binding Solution (1:2200 dilutions of IMAP beads in 1X Binding Buffer). The plates are incubated at room temperature for an additional 0.5 hours to allow complete binding of phosphopeptides to the IMAP beads. Plates are read on the LJL Analyst.
Cell Research:

[1]

- Collapse
  • Cell lines: BRAF-mutant or RAS-mutant tumor lines
  • Concentrations: ~10 μM
  • Incubation Time: 5 days
  • Method:

    Cell proliferation experiments are performed in a 96-well format (six replicates), and cells are plated at 4,000/well density. At 24 h after cell seeding, cells are treated with DMSO or 9 point IC50 dilution (0.001-10 μM) at 1% DMSO final for all concentrations. Viability is assayed on 5 days after dosing using ViaLight luminescence kit following the manufacturer’s recommendations. For cell line panel viability assay, cells are treated with SCH772984 for 4 days and assayed by CellTiterGlo luminescent cell viability assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Nude mice
  • Dosages: 12.5 mg/kg, 25 mg/kg, 50 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (23.82 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
0.6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 587.67
Formula

C33H33N9O2

CAS No. 942183-80-4
Storage powder
in solvent
Synonyms N/A
Smiles C1CN(CC1C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC=NC=C4)CC(=O)N5CCN(CC5)C6=CC=C(C=C6)C7=NC=CC=N7

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to inhibit Erk1/2 by treating the mice with the inhibitor. by what kind of administration way and at what concentration could it be done?

  • Answer:

    SCH772984 can be administrated by I.P. The dosages can be used as: 12.5 mg/kg, 25 mg/kg, 50 mg/kg. For more detail information please find the paper below: http://cancerdiscovery.aacrjournals.org/content/3/7/742.full

ERK Signaling Pathway Map

Tags: buy SCH772984 | SCH772984 supplier | purchase SCH772984 | SCH772984 cost | SCH772984 manufacturer | order SCH772984 | SCH772984 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID